GERMONE SOUTHALL: Open Payments
NPI 1710438163 · EVERETT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,071 in 50 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $726 · 2025 $1,071
Food & beverage: $1,071
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $222 |
| Neurocrine BioSciences, Inc. | 7 | $154 |
| Otsuka America Pharmaceutical, Inc. | 7 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $140 |
| Vanda Pharmaceuticals Inc. | 5 | $117 |
| Alkermes, Inc. | 5 | $107 |
| Janssen Pharmaceuticals, Inc | 3 | $87 |
| E.R. Squibb & Sons, L.L.C. | 2 | $59 |
| Axsome Therapeutics, Inc. | 2 | $35 |
Products named: AUSTEDO XR, INGREZZA, CAPLYTA, FANAPT, ARISTADA, REXULTI, INVEGA SUSTENNA, COBENFY.
Industry payments across WA — which companies pay providers there.
